work a clinical programme was started at the Peter Bent Brigham Hospital using Aziothioprine as the main immunosuppressant. 6 The early results were disappointing until corticosteroids were added to the regimen. This combination developed enthusiastically by Dr. Starzl in Denver was used in kidney transplantation by approximately ten centres worldwide. 7 In 1963 Dr. Starzl performed the first clinical liver transplant, but the patient and three others did not survive long enough to justify the procedure, so a moratorium was established on liver transplantation for four years in Denver. 8 Some of the pigs which had liver transplants survived for many years without immunosuppression at any stage. 9 The technique worked out in the pig was then applied to man in 1968 in Cambridge 10 and at about the same time Dr. Starzl had resumed his clinical programme in Denver 8 . The search for better immunosuppression led to some effective polyclonal antilymphocyte globulin preparations developed by Woodruff in Edinburgh, Starzl in Denver and Najarian in Minneapolis. They found it difficult to obtain consistently effective non-toxic products, but gradually refinements in production yielded better results.
The next important improvement in immunosuppression was the development of Cyclosporin, from the Sandoz laboratory by Borel using in vitro studies of antibody formation and skin grafts in mice. 11 Cyclosporin was investigated and was found to be extremely effective in prolonging heart allografts in rats, kidney allografts in dogs, liver and cardiac allografts in pigs. [12] [13] [14] This led to the first use of Cyclosporin in clinical organ transplantation in Cambridge. 15 The dose derived from the animal experiments proved to be much too high, and a side effect of Cyclosporin in man, not observed in animals, was nephrotoxicity which, once recognised, resulted in drastic dosage adjustment.
Cyclosporin was a watershed in organ transplantation and enabled much better early results with liver, heart and eventually lung and pancreas transplants. Instead of approximately ten centres worldwide performing solid organ transplants, soon there were more than 1000. A standard regimen of immunosuppression was Aziothioprine, steroids and Cyclosporin attempting to obtain maximum immunosuppression and minimum side effects of each individual agent.
In Cambridge an active programme of kidney and liver transplantation was established and the first vascularised pancreas transplant 16 in the UK was performed in the Cambridge unit, as was the first intestinal transplant 17 and the first heart, lung and liver transplant in collaboration with the associated cardiovascular unit in Papworth. 18 The Cambridge department had a special interest in developing better immunosuppression. Prograf (Tacrolimus) had been shown to be an effective immunosuppressant by Ochiai in Japan. 19 This work was repeated and then moved to larger animals where considerable toxicity was observed. 20 Another macrolide, Rapamycin, was investigated and found to be slightly less toxic. 21 The mechanism of action was later found by others to be different from the calcinurin inhibitors. Rapamycin alone is not nephrotoxic; it was first used in the clinic in Cambridge and was found to be a useful additional immunosuppressant but not so powerful as the calcinurin inhibitors. In the meantime Pittsburgh group under Dr. Starzl had demonstrated the value of Prograf in clinical transplants, where the toxicity in man was shown to be less than in the large animal studies in Cambridge. 22 Monoclonal antibodies were first discovered in Cambridge by Kohler and Milstein. 23 Waldmann and colleagues in the Dept. of Pathology found an extremely powerful lympholytic monoclonal antibody called Campath 24 (named after the Cambridge Dept. of Pathology). This is derived from rats and is effective against the human CD52 epitope present on all lymphocytes. This antibody was used to treat rejection in Cambridge and was found to be very effective but the patients had a high incidence of dangerous viral infections. 25 The humanised version of the antibody was used as a induction agent in kidney transplants after reports from Wisconsin which suggested that powerful induction with an "immunotoxin" could produce long lasting immunosuppression without any other drugs in monkeys with renal allografts. 26 The use of Campath combined with very low maintenance immunosuppression, half-dose of Cyclosporin instead of full-dose of three drugs, has been followed up for more than eight years now with encouraging results. 80% of the patients have not received any maintenance cortiocosteroids so this form of immunosuppression which has been called prope (almost) tolerance results in good graft survival, an excellent quality of life for most patients and considerable reduction in the cost of maintenance immunosuppression. [27] [28] [29] Gene therapy for the treatment of diabetes and haemophilia using the human insulin and factor VIII genes and the Lentivirus as a vector has now been attempted. This work has reached a stage for study in large animals. A novel source of foetal stem cells taken from the lining of the human umbilical cord is used in these experiments. The cells, which are of two types, epithelial and mesenchymal, proliferate extremely well. One million cells after two weeks are expanded to one billion. Gene therapy is studied in two ways; one via transfection in vitro of amnion cells and then transplanting the amnion cells into diabetic or haemophilic animals. The amnion cells have been studied also from the point of their apparent lack of immunogenicity. They secrete HLA-G which has a powerful immunosuppressive effect and maybe part of the mechanism by which the mother and foetus can live in harmony. 30 A similar vector to the one used in Singapore has been used by another group in Sydney and has made an important advance in transfection, by injecting the vector into temporarily ischaemic livers of diabetic rats and mice. 31 This work is at an early stage but if the results obtained in rodents in Sydney can be reproduced in diabetic dogs, this would be a significant advance with the prospect of clinical application. The technique depends on rendering the liver temporarily ischaemic. It requires a major surgical procedure and therefore investigation of simpler, less traumatic methods of obtaining a similar high level of transfection is now being made.
Kuss R, Ourget B. An illustrated history of organ transplantation. The great Adventure of the Century. Sandoz 1992.
5.
Calne 
Introduction
Preventive vaccination is the most successful medical intervention of all times. Therapeutic vaccination is not yet a recognized treatment modality in any disease, let alone cancer. Nevertheless many attempts at cancer immunotherapy have been conducted. 1,2 Particularly in melanoma, occasional impressive clinical responses have been noted in a small minority of patients, but the overall results were disappointing. 2 Our group has argued for some time that perhaps the mode of vaccination is essential for achieving therapeutic results in established disease. [2] [3] [4] [5] Most preventive vaccines are based on the induction of neutralizing antibodies to the surfaces of viruses or bacteria. Therapeutic vaccines, in contrast, require induction of robust cell-mediated immunity, capable of attacking and eliminating abnormal antigen-bearing cells. It is precisely in this area that our group has made substantial progress in recent years in pre-clinical mouse 6 and rabbit 7 models, which has culminated in clinical trials 8, 9 .
A very popular approach to therapeutic cancer vaccination has been vaccination with exact MHC-(HLA-) binding peptides derived from the sequence of tumor-associated antigens. [2] [3] [4] [5] Our group has reported more than 10 years ago that such a vaccination approach is far from optimal, because it can lead to immunological tolerance towards the immunizing antigen, rather than immunity. [10] [11] [12] The only mode of immunization by which tolerance induction by exact MHC class I binding peptides could be avoided was ex vivo peptide loading on dendritic cells (DC), followed by injection of the peptide-loaded dendritic cell. 13 Deregulated expression of MYC occurs in about 30% of human cancers, including a substantial fraction of commonly occurring cancers such as colon, prostate and breast carcinomas. MYC is a helix-loop-helix leucine zipper transcription factor that heterodimerizes with a partner protein MAX, which is regulated by a network of protein-protein interactions with MAD and MXI1 proteins. 1,2 Upon heterodimerization, MYC-MAX binds DNA sites termed Eboxes (S'-CACGTG-3') to activate or repress transcription as well as modulate chromatin. 3, 4 In the milieu of Mad proteins, MYC competes via mass action to heterodimerize with MAX. Hence, upon serum stimulation, the induction of MYC results in a rapid rise in levels of MYC that can effectively dimerize with MAX, but with limiting nutrients or growth factors, MYC levels decrease, resulting in the cessation of cell proliferation with the dominance of Mad-MAX heterodimers.
The hypoxia inducible factors, HIF-1 and HIF-2, provide transcriptional homeostatic responses to limited oxygen levels that are prevalent in both physiological and pathological conditions. [5] [6] [7] The Hif family comprises three members, HIF-1, HIF-2 and HIF-3, with the function of the latter being poorly understood. 5 HIF-1 is ubiquitously expressed, whereas HIF-2 is expressed in endothelial cells and in kidney, heart, lungs and small intestine. 5 Each Hif heterodimer consists of an oxygen-dependentsubunit and a constitutively expressed subunit. Under normal oxygen tension, the Hif subunits are constitutively synthesized and hydroxylated by prolyl hydroxylases (PHDs), which target the modified subunit for recognition by the von Hippel-Lindau (VHL) protein and subsequent degradation by proteasomes. 8 Hence, Hif activity is regulated by a cycle of synthesis and oxygen-dependent degradation under normal oxygen tension conditions. In hypoxic conditions, decreased molecular oxygen substrate diminishes the enzymatic activity of PHDs that are further inhibited by reactive oxygen species (ROS) released from inefficient respiring mitochondria. [9] [10] [11] The ROS oxidize and inactivate the ferrous ion within the PHD active sites rendering the PHDs incapable of hydroxylating Hif subunits. 12 The stabilized Hif heterodimers bind and transactivate genes involved in pH regulation, glucose transport, glycolysis and vasculogenesis, allowing for cellular adaptation to hypoxia. 5, 7, 8 Similar to MYC, HIF-1 activates virtually all genes involved in glycolysis, but unlike MYC, HIF-1 actively inhibits mitochondrial respiration. [13] [14] [15] Although physiological HIF-1 responses can inhibit the activity of normal MYC, the deregulated expression of oncogenic MYC collaborates with HIF to confer the tumor metabolic phenotype that is described as the Warburg effect, or aerobic glycolysis. 6 In this regard, the context in which Myc mediates transcription is critically important for tumor progression. 4, 16 The MYC proto-oncogene is a classical immediate early serum response gene that is under tremendously complex transcriptional control, such that cis-elements regulating MYC tightly adjust its level of expression. 17, 18 This is not surprising as MYC has significant oncogenic potential through its activity as a transcription factor. The most conserved set of MYC target genes are involved in ribosomal biogenesis. Drosophila that express hypomorphic dMyc alleles phenocopy flies with mutant ribosomal subunits -small body size, a phenotype termed 19, 20 In fact, genes such as NPM1 (encoding nucleophosmin) and NCL (encoding nucleolin), which are involved in ribosomal biogenesis, are some of the most consistent MYC target genes among many different cells types. 21, 22 MYC also directly activates RNA polymerases I and III dependent genes that are necessary for ribosomal assembly. [23] [24] [25] In addition, MYC regulates genes involved in glucose metabolism, although this could be a later evolutionary event particularly found in mammalian systems. 26-28 MYC binds to and regulates virtually all glycolytic enzyme genes and many genes involved in mitochondrial biogenesis. 5, 29 As such, it is presumed that MYC's role in normal cellular metabolism is through stimulating glycolytic flux for oxidative phosphorylation.
When the oxygen supply is depleted, normal cells become hypoxic, which results in the expression of Hifs and a decrease in the expression level of MYC. The Hifs induce genes that permit adaptation to hypoxia. Two recent studies demonstrate that HIF-1 induces pyruvate dehydrogenase kinase 1 (PDK1), which phosphorylates and inactivates pyruvate dehydrogenase (PDH), a mitochondrial enzyme that catalyzes the conversion of pyruvate to acetyl-CoA ( Fig. 1) . Acetyl-CoA is a key substrate for the Krebs cycle, such that its depletion results in diminished hypoxic mitochondrial respiration. 30,31 Presumably, decreased mitochondrial respiration in hypoxia reduces toxic ROS generated by inefficient respiration. In this regard, HIF-1 also reduces ROS by optimizing respiration efficiency via inducing cytochrome c oxidase subunit IV, isoform 2 (COX412) that replaces the less efficient non-hypoxic COX411 isoform. 32 These isoforms are components of cytochrome oxidase that transfers electrons to oxygen. Hence, the more efficient transfer by COX412 diminishes ROS production under hypoxic conditions. We tested whether the anti-oxidants vitamin C and N-acetylcysteine (NAC) could squelch ROS, diminish DNA damage and genomic instability and in turn inhibit tumor formation. Using a transgenic mouse liver cancer and human xenograft models of lymphoma and prostate cancer, we observed a dramatic inhibition of tumorigenesis by antioxidants, particularly NAC. We studied the human lymphoma xenografts and found no significant genomic instability or its attenuation by NAC in this model. We tested whether reduction of ROS could decrease HIF-1 levels by re-activating PHDs under hypoxia 12 and found that both NAC and vitamin C could inhibit tumorigenesis and reduce HIF-1 levels significantly in vitro and in vivo. The dependency of these P493 tumors on HIF levels was demonstrated by the rescue from these anti-oxidants by a stabilized mutant form of HIF-1 that is oxygen insensitive. Furthermore, reduction of HIF-1 through the use of two independent short hairpin RNA (shRNA) vectors dramatically decreased tumorigenesis.
When MYC is ectopically expressed (mimicking MYC overexpression in human tumors), we found that MYC cooperates with HIF1 to induce the expression of PDK1, hexokinase 2 (HK2, known to be a target of both HIF and MYC) (Fig. 1) , and vascular endothelial growth factor (VEGF) in human P493 B cells. 40 It is notable that high levels of MYC have been found to bind a new set of target genes, suggesting that the behavior of MYC depends on its level. 22 So, when MYC is over-expressed, it cooperates with HIF to alter cellular metabolism in favor of glycolysis with increased production of lactate. This phenomenon is also known as the Warburg effect.
Over 80 years ago, Warburg described through studies of animal and human cancer tissue sections ex vivo that cancer tissues have increased glucose uptake and tend to convert glucose to lactate rather than to carbon dioxide via oxidative phosphorylation. 41, 42 Aerobic glycolysis or the Warburg effect has been literally interpreted as the propensity for cancer cells to convert glucose to lactate in the presence of adequate oxygen levels ( Fig.  1) . Anaerobic glycolysis, on the other hand, is the conversion of glucose to lactate in the absence of adequate oxygen.
In contrast to normal cells, tumor cells exist in a hypoxic microenvironment due to abnormal neovasculature, but can also display increased glycolysis due to genetic alterations. 43, 44 The dramatic increase in glucose uptake by tumors is the basis for diagnostic and prognostic positron emission tomography (PET) scanning of tumors. 45, 46 It also signifies a significant therapeutic window between cancers and normal tissues for targeting glucose metabolism. Aerobic glycolysis results from genetic alterations in oncogenes that drive glycolysis and increase the conversion of pyruvate to lactate. For example, MYC, Ras, Akt and loss of VHL that stabilizes HIF-1 can all contribute to the Warburg effect. 47 It should be noted that increased levels of glycolytic enzymes resulting from the Warburg effect could also contribute to tumor adaptation through alternative non-glycolytic functions of these enzymes including autophagy, which recycles damaged organelles as an alternative fuel source for cells suffering metabolic stress from limited oxygen and nutrients. An adaptive response to the hypoxic tumor microenvironment can also stabilize HIF-1 which further contributes to increased glucose uptake through induction of the glucose transporter GLUT1 and lactate production through the induction of LDHA by tumors (Fig. 1) . It has been shown that a subset of mesenchymal stem cells (MSCs) is an excellent source of IL-1 Ra, which in addition to their regenerative capacity makes these cells a potential therapeutic agent in the treatment of diabetes mellitus. 5 We review here the present understanding of the potential use of IL-1Ra and mesenchymal stem cells as modulators of diabetogenesis.
IL-1Ra in Type 1 Diabetes
IL-1Ra is a naturally occurring cytokine. It is an inhibitor of IL-1 and IL-1 . It binds to IL-1 receptors and by that it antagonizes the inflammatory effects of IL-1 and IL-1 . 6 When IL-1 occupies its receptor, various pro-inflammatory events are initiated. Activated cells release highly inflammatory substances such as nitric oxide. 6 In addition, binding of IL-1 to its receptor induces the synthesis and release of chemokines that attracts neutrophils, macrophages and lymphocytes resulting in tissue inflammation. 7 When IL-1Ra binds to the IL-1 receptor, no such events are initiated, and binding of IL-1 is blocked by IL-1Ra which does not transduce signals. 8 IL-1Ra is produced by immune cells, 9 stromal cells, 10,11 adipocytes, 13 epithelial cells, keratinocytes 14, 15 and hepatocytes. 16 It appears that deregulation in the balance between IL-1 and IL-1Ra is important in the pathogenesis of diabetes mellitus type 1 and diabetes mellitus type 2 [7] . 7 The IL-1Ra/IL-1 ratio is significantly different in newly diag-nosed and long-standing diabetes mellitus type 1 patients. The IL-1Ra/IL-1 ratio is strongly reduced in newly diagnosed diabetes mellitus type 1 patients compared with healthy population. At the onset of disease there is an imbalance in favor of pro-inflammatory IL-1 which induces apoptosis in insulin-producingcells. During the evolution of disease, after all beta cells are damaged, the inflammatory process in pancreas ceases with decreased production of IL-1 resulting in an increase in IL1Ra/IL-1 ratio. Also, the serum concentration of IL-1Ra increases during the course of the disease. While in newly diagnosed diabetes mellitus type 1 patients serum concentration of IL1Ra is similar to that of healthy individuals, the level of IL-1Ra in serum of long-standing diabetes mellitus type 1 patients is significantly higher compared with the serum of healthy individuals and compared with that of newly diagnosed diabetes mellitus type 1 patients. 17 IL-1 has a lytic effect on the islet cells which was clearly demonstrated in vitro. 18 In addition, intraperitoneal administration of IL-1 accelerates the onset of diabetes mellitus type 1 in the BB rats 19 and induces hyperglycemia and hypoinsulinemia in normal Wistar Kyoto Rats. 20 In vitro IL-1Ra can protect insulinproducing cells from the deleterious effects of IL-1. 21 Exposure (1-2 h) of rat and mouse pancreatic islets to 10 ng/ml recombinant IL-1 beta induced a 70-80% inhibition of insulin response to glucose after 12 h. Co-incubation with 100 ng/ml IL-1Ra efficiently counteracts these effects of IL-1 beta. The importance of these results can be seen not only in the suggestion that IL-1Ra can protect insulinproducing beta cells from damaging effects of IL-1, but also in showing that insulinproducing beta cells possess type I interleukin-1 receptors that indicates potential therapeutic use of IL-1Ra in the treatment of diabetes mellitus. 21 In vivo blocking of IL-1 receptors by IL-1Ra
modulates the deleterious effect of IL-1 on pancreatic beta cells. 22 After the induction of diabetes mellitus by using streptozotocin (STZ), mice were injected repeatedly (10 daily injections) with either rat IL-1 inhibitor (IL-1 INH) derived from glucocorticoid-treated macrophages, 23 or with recombinant DNA produced human IL-1Ra. Mice treated with either of these agents remained normoglycemic. In comparison with rat IL-1 INH, human IL-1Ra had milder but still significant protective effect. 22 In humans there is positive correlation between IL-1Ra and C-peptide secretion and IL1Ra was found to be elevated in patients with increased C-peptide secretion. 24 There is also a positive association of IL-1Ra with body mass index (BMI) confirming adipose tissue as an important source of IL-1Ra. 25 However, IL-1Ra showed positive correlation with C-peptide secretion without adjustment for BMI percentiles, suggesting other sources of IL-1Ra. 24 These data suggested that anti-inflammatory IL-1Ra, as the specific receptor antagonist of IL-1 , by binding to IL-1 receptors, antagonizes the inflammatory effects of IL-1 and preserves -cell function in type 1 diabetes. Therefore, IL1Ra might be a new therapeutic agent in diabetes mellitus type 1. 23 A high molar excess of IL-1Ra over IL-1 seems to be necessary to prevent IL-1 mediated -cell toxicity. 26 Sustained administration of IL-1Ra can prevent experimental diabetes mellitus elicited by multiple low-dose STZ treatment. 27 After 5 days of STZ treatment (40mg/kg body weight), mice were injected with IL-1Ra (8 mg/kg body weight). The IL-1Ra was delivered with a subcutaneous implanted osmotic pump. The IL1Ra administration (8 mg/kg body weight every day) started on the last day of STZ treatment and injected continuously for 12-14 days. Mice were normoglycemic up to the 19 th day of the experiment. However, the mice become hyperglycemic in the following 10 days after cessation of the delivery of IL-1Ra. Morphological examination showed significantly lower degree of islet mononuclear cell infiltration on day 19 compared with day 29. On day 29, the majority of the pancreatic islets were infiltrated with mononuclear cells. 27 Thus continuous administration of IL-1Ra prevents pancreatic mononuclear cell infiltration, islet destruction and hyperglycemia in STZ-induced diabetes mellitus.
Several lines of evidence have shown that IL-1 impair glucose-stimulated insulin production in mouse, rat and human islets 28-30 and there is evidence that IL-1 beta has a deleterious action on beta-cell replication resulting in abnormal pancreatic function and hyperglycemia. 31 Apparently this can be prevented by IL1Ra adenoviral overexpression. In the in vitro experiment which used human pancreatic islets, 31 adenoviral gene delivery of the cDNA encoding the IL-1Ra to cultured islets resulted in islet protection. 31 These results further support the idea that in vivo gene therapy can be used to prevent insulinitis and the consequent diabetes mellitus.
IL-1Ra in Type 2 Diabetes
Besides the role in the evolution of diabetes mellitus type 1, IL-1 and IL-1Ra appear to play an important role in the pathogenesis of diabetes mellitus type 2. 2, 3, 8, 33 Although the precise mechanism of beta cell failure in diabetes mellitus type 2 is still unknown, metabolic stress caused by repetitive glucose excursions, dyslipidemia and increased levels of adipokines can induce an inflammatory response characterized by local cytokine secretion, islet immune cell infiltration and -cell apoptotic death which can be important in the pathogenesis of diabetes mellitus type 2. [33] [34] [35] [36] Beta cells were identified as the cellular source of glucose-induced IL-1. 35 High glucose levels increase beta-cell production and release of IL-1 and is followed by beta cell apoptosis and insulin resistance. 37 The IL-1 beta mRNA expression is increased in -cells of patients with type 2 diabetes. 38 Based on these findings, several lines of evidence indicate that IL1Ra can be used as a therapeutic agent in the treatment of diabetes mellitus type 2. 39-41
When IL-1Ra was injected in C57BL/6J mice, previously fed a high-fat/high-sucrose diet (HFD) for 12 weeks, glucose tolerance and insulin secretion were improved. 39 IL-1Ra was used in the clinical trial as a therapeutic agent for the treatment of diabetes mellitus type 2. 40 Patients received either placebo or a subcutaneous injection of 100 mg ''anakinra''-recombinant human IL-1Ra once daily for 13 weeks. At the end of the trial, the HbA1c level was lower in the IL-1Ra -treated group than in the control group. Further, the decrease of serum IL-6 and C-reactive protein levels, as markers of systemic inflammation, was noticed after IL-1Ra therapy. 40 It was assumed that recombinant human IL-1Ra improved glycemic control in patients with diabetes mellitus type 2 probably through enhanced secretory function of pancreatic beta cells. 40 The body mass index (BMI) of patients remained stable during the experiment implying that recombinant human IL-1Ra is not an anorexigenic agent. 40 Also, systemic hypoglycemia was not reported by any of IL-1Ra treated patient. 40 A concern with the use of IL-1Ra is the potential increase in the incidence of infectious disease because of IL-1 blockade. However, this unwanted effect was not seen in more than 100,000 patients with rheumatoid arthritis who underwent long-term treatment with recombinant human IL-1Ra. 41 Importantly insulin resistance, insulin-regulated gene expression in skeletal muscle and serum adipokine levels were all unaffected by therapeutic use of IL-1Ra. 40 It is therefore possible that long-term and higher doses of IL-1Ra therapy or treatment with other recombinant IL-1Ra that has a longer half-life than anakinra (anakinra has a short half-life, 6-8 hours) should prevent beta cell destruction and promote beta cell regeneration in patients with diabetes mellitus type 2.
Mesenchymal Stem Cell Therapy of Diabetes Mellitus
MSCs are self-renewable multipotent stromal cells that can be found in almost all postnatal tissues. 42, 43 The most often used source tissues, for isolation of MSCs are bone-marrow, 44, 45 adipose tissue 46 and umbilical cord blood, 47, 48 but MSCs can also be derived from virtually all tissues. [49] [50] [51] There are two main MSC characteristics currently used for their isolation and identification: capacity for self-renewal and differentiation into tissues of mesodermal origin (for example bone, cartilage, and adipose tissue) and lack of expression of surface markers characteristic of hematopoietic cells (CD14, CD34, CD11a/LFA-1, and CD45), erythrocytes (glycophorin A), and platelet and endothelial cell (CD31). 52, 53 MSCs show variable levels of expression of several molecules: CD105 (SH2), CD73 (SH3/4), CD44, stromal antigen 1, CD166 (vascular cell adhesion molecule), CD54/CD102 (intracellular adhesion molecule), and CD49. 52, 53 It had been suggested that MSCs have immunomodulatory capacity. 54 MSCs inhibit T cell proliferation by several pathways: by engagement of the inhibitory molecule programmed death 1(PD-1) to its ligands PD-L1 and PD-L2, 55 by producing factors which suppress their proliferation (such as TGF beta or IL-10) 56, 57 and through "tolerogenic" interaction with dendritic cells (DCs). 57 There also findings indicating that MSCs can render T-cells anergic. 58 This probably depends on their affect on differentiation of monocytes to DCs or on inhibiting DCs maturation. 54 Immature DCs can render T cells anergic. 59 MSCs can also alter the cytokine secretion profile of dendritic cells resulting in increased production of antiinflammatory cytokine IL-10 and decreased production of inflammatory cytokines IFNand IL-12. 54 Furthermore, MSCs may regulate immune response by increasing number of CD4 + CD25 + FoxP3 + downregulatory T cells. 60 Bone marrow-derived MSCs also have inhibitory effects on the proliferation and IgG secretion of -cells as shown in BXSB mice experimental model for systemic lupus erythematosus. 61 One of the possible pathway of MSCs effects on inflammation is the expression of IL-1Ra. Recently a well characterized subpopulation of MSC which express IL-1Ra has been described. 5 IL-1Ra expressed by MSCs is biologically active, antagonizes IL-1-and blocks release of TNF-from activated macrophages in vitro. 5 Considering that TNF-and IL-1-are very important cytokines in inflammatory reactions, [62] [63] [64] [65] blocking their function, by MSCs which express IL-1Ra, protects tissues from inflammation-induced injuries.
IL-1Ra-expressing subpopulation of MSCs can also modulate the inflammatory response in vivo. This was shown in the experiment in which IL-1Ra-expressing subpopulation of MSCs inhibited bleomycin (BLM)-induced inflammation and fibrosis in the lungs of mice. MSCs were more effective than recombinant IL-1Ra, delivered systemically or by viral infection, in inhibiting immune cell trafficking and cytokine expression levels. 5 Although there are significant differences in the number of MSCs in different species (IL1Ra-expressing subpopulation of MSCs is more abundant in murine than in human population), IL-1Ra expression by MSCs is conserved across species. 5 These findings implied that IL1Ra-expressing subpopulation of MSCs, independently of their origin, may be used as a cellular vector for down regulated diabetogenesis. It has been shown that infusion of human MSC (hMSCs) in multiple low dose STZinduced diabetic, immunodeficient mice (NOD/SCID) reduced glycemic levels and increased peripheral insulin levels. 66 Similarly, 5 x 10 5 mouse mesenchymal stem cells given at the end of diabetes induction with multiple low doses of streptozotocin prevented or delayed onset of glycemia and glycosuria in male C57BL/6 mice (our work in progress).
Systemic MSC administration also resulted in beta-cells regeneration and prevented renal damage in this model of diabetes. 67 Bonemarrow derived mice MSCs were injected intravenously, as a single dose, in diabetic mice when hyperglycemia, glycosuria, massive beta-pancreatic islets destruction, and mild albuminuria were evident without renal histo-pathologic changes. Thus, MSCs were injected when mice had symptoms similar to symptoms of human patients diagnosed with type 1 diabetes mellitus. Glycemic levels were significantly reduced one week after MSCs injection. Euglycemic values in mice that received MSCs were seen about one month after MSCs treatment. Normal values of glycemia in MSCstreated mice lasted at least for two months (till the end of experiment) and during that period correlated with glycosuria reversion. 67 Pancreatic islets in mice that received MSCs were architecturally organized as in normal mice. 67 On the contrary, pancreatic islets were destroyed by inflammation in control diabetic mice. Although with normal structure, islets in MSCs-treated diabetic mice were smaller than islets in normal mice, probably because MSCs didn't completely regenerate pancreatic islets. Morphologic analysis of these islets showed that MSC administration increased the number of insulin-producing cells and restricted expansion of glucagon-producing cells. 67 These results suggest that corrections of blood glucose level happened due to regeneration of the pancreatic islets.
Systemic MSCs administration also recovered and prevented further impairment in renal function. 67 Two months after MSC administration, histologic kidney analyses showed normal architecture of glomeruli and reduced albuminuria was observed in MSC-treated diabetic mice. Glomeruli in control diabetic mice showed hyalinosis, mesangial expansion and increased albuminuria. 67 MSC transplantation can reduce cardiovascular complications and improve cardiac function in STZ-induced diabetic rats. 68 Bone marrow derived MSCs administered systemically or locally at the wound site accelerate wound healing in diabetic rats. 69 Through paracrine actions of growth factors secreted by MSCs diabetic polyneuropathy was improved by MSCs treatment, which was also shown in diabetic rats. 70 These results suggest that bone marrow-derived MSC therapy could be considered for the treatment of diabetes mellitus type 1 and for the complications of diabetes mellitus: nephropathy, cardiovascular complications, polyneuropathy, delayed and poor wound healing. [67] [68] [69] [70] Besides these promising results, shown in animal models of diabetes mellitus, there are several problems which limit the therapeutic use of MSCs in humans. 71, 72 There is a potential risk for malignant transformation of MSCs because of their chromosomal instability, registered in vitro. 71 Nevertheless, malignant transformation of human MSCs has not been noted till now. 54 MSCs have a potential to differentiate into other, unwanted mesenchymal lineages which could also be problematic for their therapeutic use in humans. 72 To prevent this unwanted MSCs differentiation, several studies were done in vitro and in vivo to define factors which influence differentiation pathways. 73 However, the roles of these factors are not completely understood and differentiation of MSCs to unwanted mesenchymal lineages is still unsolved problem.
Concluding Comment
Experimental evidence indicates that IL-1Ra and MSCs are potential therapeutic agents in the treatment of diabetes mellitus type 1 and diabetes mellitus type 2. Initial clinical trials of the effect of IL-1Ra in type 2 diabetes are encouraging. Furthermore, experimental data suggest that MSCs could be used for prevention and treatment of complications of diabetes mellitus. However, there are still problems in the broader use of IL-1 Ra and MSCs in humans such as: short-half life of human recombinant IL-1Ra, potential increase in the incidence of infectious disease because of longlasting IL-1 blockade or potential risk for malignant transformation of MSCs and their unwanted mesenchymal lineages differentiation.
Solving these problems could improve efficacy of IL-1Ra and MSCs that would recommend them as novel therapeutic agents in diabetes mellitus. 
Introduction
Caffeine (1,3,7-trimethylxanthine) is a widely used substance. A primary effect of this compound is activation of Ca 2+ channels in plasma membranes and endoplasmic reticulum (ER), resulting in a rapid Ca 2+ release into the cytosol and neighboring mitochondria. [1] [2] [3] [4] [5] [6] [7] [8] This process is prevented by the Ca 2+ channel blocker verapamil 9 and the protonophore carbonyl cyanide m-chlorophenyl-hydrazone (CCCP). 6 Other mechanisms of action include inhibition of phosphodiesterases (at high concentrations) and adenosine receptors. [10] [11] Caffeine has also been shown to potentiate the mutagenic and toxic effects of anticancer drugs and radiation. 12 It has been suggested that caffeine binds to damaged regions of the DNA and interferes with binding of repair enzymes. The drug also acts as a "G2 checkpoint" inhibitor via dephosphorylation of the cell division cycle-2 (CDC2), a key component in the transition from G2 phase to M phase [12] [13] [14] .
The endoplasmic reticulum (ER) is a major intracellular Ca 2+ pool. It releases Ca 2+ via mechanisms involving ryanodine and inositol 1,4,5-trisphosphate (IP3) receptors. Ca 2+ stores are replenished via ER-ATPases, which actively transport Ca 2+ back to the ER pool. 8 Studies have shown that mitochondria reverse the increased cytosolic Ca 2+ via the activity of "Ca 2+ uniporters"; these channels are stimulated by high intracellular Ca 2+ during cell activation, returning the cell to Ca 2+ homeostasis. [15] [16] [17] In certain cell types, mitochondrial functions can become impaired by the Ca 2+ flooding. 1, 3, 4, 6 The impact of caffeine on cellular bioenergetics is not fully understood. We studied here its effects on mitochondrial O2 consumption (respiration) in HL-60 (myeloid) cells, Jurkat (lymphoid) cells and isolated mitochondria from beef heart. We also investigated whether Ca 2+ flooding could mediate the effect of caffeine on the mitochondria.
Materials and Methods Reagents
Pd (II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin sodium salt (Pd phosphor) was purchased from Porphyrin Products (Logan, UT Pd phosphor was dissolved at 2.5 mg/mL (2.0 mM) in dH2O and stored at -20 o C in small aliquots. NaCN (1.0 M) was freshly made in dH2O and the pH was adjusted to ~7.0 with 12N HCl immediately prior to use.
Cells
The human promyelocytic leukemia (HL-60) and T-cell lymphoma (Jurkat) cells were purchased from American Tissue Culture Collection (Manassas, VA). The cells were cultured in RPMI-1640 media plus 10% fetal bovine serum, 1% L-glutamine and 1% penicillin/streptomycin. The doubling time for these cells was about 24
hr. Cell count and viability were determined by light microscopy, using a hemocytometer and standard trypan blue staining. The presence of Pd phosphor had no notable adverse effects on the cells. 18
Mitochondria
Beef heart mitochondria were prepared as described by Blair 19 and resolved into heavy and light fractions. Only the heavy fractions were used.
Mitochondria were suspended in 10 mM Tris-Cl (pH 8.2), 250 mM sucrose, 2 μM Pd phosphor and 0.5% albumin (with or without 1.41 mM CaCl2). O2 consumption was initiated with 10 mM succinate.
Cellular Respiration
O2 consumption was measured at 37 o C in an instrument described earlier, [19] [20] [21] which monitors the phosphorescence of a palladium (Pd) phosphor included in the reaction mixtures. The probe was excited by pulsed light (10 per sec) that peaked at 630 nm. The emitted phosphorescent light was isolated by an interference filter centered at 800 nm and passed through to a Hamamatsu photomultiplier tube. The signal was digitalized using PCI-DAS4020/12 analog input board. The phosphorescence lifetime ( ) and decay constant (1/ ) were used to calculate [O2]:
where 1/ 0 is the decay rate in the absence of O2. Titration of dissolved O2 with ascorbic acid in the presence of ascorbate oxidase was used to calibrate the phosphorescent signals. 20, 21 Through this calibration, the quenching constant kq was 96.1 + 1.2 μM -1 s -1 and 1/ 0 10087 + 1566 s -1 . 20 Respiration was measured at 37 o C using glucose as a substrate. For each run, 1.0 mL of the cell suspension was placed in a 1-mL glass vial. The vial was sealed with a crimp top aluminum seal. Mixing was with a parylenecoated stirring bar. The rate of respiration was the negative of the slope of [O2] vs. t (k, in μM O2 min -1 ). Addition of NaCN resulted in inhibition of O2 uptake, demonstrating the decline in [O2] was mainly due to mitochondrial consumption. The k-value without added cells (instrument drift) with and without 3.0 mM caffeine was < 0.037 μM O2 min -1 .
Statistical significance between the k-values in treated and untreated samples was determined by paired Student's t-test. A value of p < 0.05 was considered significant.
Results
The effects of caffeine (the powder formulation without vehicle) on HL-60 and Jurkat cellular respiration are shown in Fig. 1A -B. The cells (10 6 per mL) were suspended in RPMI-1640 cell culture media supplemented with 2 μM Pd phosphor and 0.5% albumin (added to stabilize the phosphoresce signal) with and without 
HL-60 cells
To measure the inhibitory effect of caffeine on HL-60 cells over a 3-hr incubation period, samples were taken concurrently every hr from the following 3 conditions: untreated, 1.0 mM caffeine and 10 mM NaCN (Fig. 1C) . The cells were prepared as in Fig. 1A , with O2 measurements taken every minute for about 1 hr. The cells remained incubated with caffeine or NaCN for the entire duration of the experiment. The values of k (μM O2 min -1 , mean + SD, n = 3) at hr 1-3 for the untreated cells were 1.1 + 0.1 and for the cells treated with caffeine 0.7 + 0.06 (~36% inhibition, p = 0.008). Thus, the inhibitory effect persisted in the presence of caffeine. O2 consumption was inhibited with 10 mM NaCN (Fig. 1A-C) , confirming that the (Fig. 1) In 27 additional experiments, HL-60 cellular respiration was inhibited by 30-53% in the presence of 50 μM to 4 mM caffeine (Fig. 1D, n > 3 per condition). Using the paired Student's ttest, there were no statistical significances in the per cent inhibition for these concentrations of caffeine. By contrast, the p value for per cent inhibition between 10 μM and > 50 μM caffeine was < 0.03. Thus, the inhibition of HL-60 cellular respiration by caffeine reached a plateau (mean + SD, 43 + 7%, n = 24) at 50 μM.
Recovery from the caffeine's effect was investigated. HL-60 cells were incubated at 37 o C in the cell culture media with and without 3.0 mM caffeine for 120 min. The cells were then washed and incubated in caffeine-free media for 60 min. At the end of the incubation period, the cells were harvested and suspended at 10 6 cells/mL in media plus 2 μM Pd phosphor and 0.5% albumin. The k-value (μM O2 min -1 ) with and without caffeine was 1.2. Thus, the inhibitory effect of caffeine on respiration was reversible in the absence of caffeine.
We also investigated the effect of "caffeine/Na benzoate" formulation on HL-60 cellular respiration. This intravenous drug is commonly used for patients. The k-value (μM O2 min -1 ) for untreated cells (10 6 per mL) was 1.1, for cells treated with 0.25 mM caffeine/Na benzoate 0.9 (18% inhibition), for cells treated with 0.5 mM caffeine/Na benzoate 0.9 (18% inhibition), and for cells treated with 1.0 mM caffeine/Na benzoate 0.8 (27% inhibition). Na benzoate alone (1.0 mM) increased the k-value by 24%. Thus, the effect of caffeine/Na benzoate on HL-60 respiration was similar to pure caffeine.
We next evaluated the role of Ca 2+ in the inhibitory effect of caffeine on HL-60 respiration. For this purpose, cellular O2 consumption was measured in phosphate-buffered-salts supplemented with 10 mM glucose with (Fig. 2B) and without ( Fig. 2A) 0.91 mM Ca 2+ . As previously suggested, 2,5 a 4-hr incubation in phosphate-buffered-salts depletes intracellular Ca 2+ stores (while shorter incubations only diminish the stores). The cells (3 x 10 6 per mL) were first incubated in the above phosphate-bufferedsalt solutions for 4 hr. Two μM Pd phosphor and 0.5% albumin with and without 3.0 mM caffeine were then added; O2 measurements were done immediately. For the cells in phosphate-buffered-salts plus 10 mM glucose plus (Fig. 2) (Fig. 2A) , the k-value (μM O2 min -1 ) for untreated cells was 1.4 and for cells treated with 3.0 mM caffeine was 0.95 (32% inhibition). For the cells in phosphate-bufferedsalts plus 10 mM glucose only (without Ca 2+ , Fig. 2B ), the k-values for treated and untreated cells were 0.8. In all conditions, respiration was almost completely inhibited with 10 mM NaCN. Thus, it appears likely that Ca 2+ mediates the caffeine's effect on cellular respiration. This possibility was further suspected by the protective effect of verapamil (a calcium channel blocker) on caffeine-induced inhibition of HL-60 cellular respiration (Fig. 3) . The cells were suspended in phosphate-buffered-salts (without Ca 2+ ) plus 10 mM glucose for 90 min; 2 μM Pd phosphor and 0.5% albumin with and without 3.0 mM caffeine and 5.0 μM verapamil were then added. The values of k (μM O2 min -1 , mean + SD, n = 3) for the untreated cells were 0.8 + 0.1, for the cells treated with caffeine alone 0.6 + 0.1 (~25% inhibition, p < 0.0001), for the cells treated with verapamil alone 0.7 + 0 (~13% inhibition, p = 0.5), and for The absence of an effect of caffeine on the respiration of isolated mitochondria from beef heart is shown in Fig. 4A-B . Mitochondria (15 μg/mL) were suspended in 10 mM Tris-Cl (pH 8.2), 250 mM sucrose, 2 μM Pd phosphor and 0.5% albumin with and without 0.25, 0.5, 1.0, 2.0, and 3.0 mM caffeine. Respiration was initiated with 10 mM succinate. The k-value (μM O2 min -1 ) for untreated mitochondria was 2.3 (r 2 = 0.986) and for mitochondria treated with 0.25-3.0 mM caffeine was (mean + SD) 2.1 + 0.06 (Fig. 4A) . The same experiment was repeated with 1.41 mM CaCl2 (the same [Ca 2+ ] as in the cell growth media) added to the above buffered solution. The k-values (μM O2 min -1 ) for untreated mitochondria and for mitochondria treated with 3.0 mM caffeine were both 1.2 (Fig. 4A) . In all conditions, O2 consumption was completely inhibited with 10 mM NaCN (Fig. 4A-B) .
Discussion
Caffeine is known to activate Ca 2+ channels on the plasma membrane and endoplasmic reticulum. [1] [2] [3] [4] [5] [6] 8 This process causes rapid increase in cytosolic Ca 2+ . Other studies also show that mitochondrial Ca 2+ uptake ameliorates the increased cytosolic Ca 2+ in activated cells until a steady state condition returns. 15 In certain cells (e.g., muscle, nerve and myeloid), mitochondrial [Ca 2+ ] may reach millimolar levels. 1 For example, in chromaffin cells, caffeine increases mitochondrial [Ca 2+ ] to about 0.5 mM. 6 This rapid Ca 2+ flood may impair mitochondrial functions, causing cellular ATP de- pletion, production of reactive O2 species (ROS) and cell death. 3 Mitochondria that are nearby (neighboring) Ca 2+ stores are more susceptible. 7 Other mechanisms of action include caffeineinduced inhibition of specific phosphodiesterases and adenosine receptors. 10, 11 Deleterious effects of caffeine also include blocking protective cellular responses to radiation (e.g., induction of G2 checkpoints, stimulation of DNA damage repair and execution of apoptosis). 13, 14 Some of these effects have been shown to potentiate the cytotoxicity of anticancer drugs and radiation. 22 We show here that caffeine rapidly inhibits respiration of the myeloid cell line, HL-60 (Fig.  1A, C and D) . By contrast, caffeine had a smaller effect on respiration of Jurkat cells (Fig.  1B) ; suggesting the caffeine's induction of mitochondrial impairment is tissue-specific. 2 In HL-60 cells, respiration is inhibited by caffeine in cell growth media (containing 1.41 mM Ca 2+ , Fig. 1A, C and D) as well as in phosphate-buffered-salts supplemented with 0.91 mM Ca 2+ (Fig. 2A) . The inhibition continues in the presence of caffeine (Fig. 1C) . However, mitochondrial recovery occurs after caffeine removal (see Results). These findings are consistent with observations showing Ca 2+ channels will remain open for the duration of caffeine exposure, while removal of caffeine reverses mitochondrial Ca 2+ flooding. 15 The effect of caffeine was not observed in the cells that were pre-incubated in phosphatebuffered-salts without Ca 2+ for 4 hr (Fig. 2B) ; a treatment that is known to deplete intracellular Ca 2+ stores. 2, 5 Moreover, the effect of caffeine was less prominent in the cells that were pre-incubated in phosphate-buffered-salts without Ca 2+ for 90 min; the inhibition was also further prevented by the Ca 2+ channel blocker verapamil (Fig. 3) . These results support the role of Ca 2+ in mediating caffeine's effects on respiration. In Fig. 3 , removal of extracellular Ca 2+ was necessary. Studies have shown a rapid equilibrium of Ca 2+ between the intracellular and extracellular compartments in myeloid cells; this process is not prevented by verapamil. 23 Furthermore, verapamil does not prevent movements of Ca 2+ cytosol to intracellular stores. 23 In lymphoid (Jurkat) cells, caffeine was less effective (Fig. 1B) , suggesting specificity with respect to caffeine-induced mitochondrial dysfunction. 6 The ability of mitochondria to modulate cytosolic Ca 2+ requires complex cellular signaling. 6 Thus, mitochondrial accumulation of large quantities of Ca 2+ did not occur in a non-cellular environment, as shown in Fig. 4 (see Results).
For HL-60 cells, impaired respiration reached a plateau (43 + 7% inhibition) at 50 μM (Fig. 1D) .
As previously shown, 6 in activated cells the proximity to Ca 2+ stores influences the extent by which mitochondrial Ca 2+ uptake occurs.
In summary, the results show caffeine impairs mitochondrial O2 consumption in malignant myeloid cells. This effect is likely to be mediated by Ca 2+ flooding into the cytosol and mitochondria. It remains unclear whether this observation could account for reported synergism between caffeine and anticancer therapy. [12] [13] [14] 
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